Human IL-27 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 5.51 pg/ml (50 μl)；17.28 pg/ml (10 μl) |
| Standard Curve Range | 13.72~10000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0348 | 0.0396 | 0.0372 | |
| 13.72 | 0.0476 | 0.0455 | 0.0466 | 0.0094 |
| 41.15 | 0.0701 | 0.0681 | 0.0691 | 0.0319 |
| 123.46 | 0.1287 | 0.1349 | 0.1318 | 0.0946 |
| 370.37 | 0.3138 | 0.3228 | 0.3183 | 0.2811 |
| 1111.11 | 0.8036 | 0.8394 | 0.8215 | 0.7843 |
| 3333.33 | 2.1080 | 2.1650 | 2.1365 | 2.0993 |
| 10000.00 | 4.1420 | 4.2020 | 4.1720 | 4.1348 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 205.1 | 1064.4 | 3596.5 | 203.0 | 1017.0 | 3373.2 |
| Standard Deviation | 5.0 | 35.7 | 123.5 | 11.8 | 29.4 | 104.1 |
| Coefficient of Variation(%) | 2.4 | 3.4 | 3.4 | 5.8 | 2.9 | 3.1 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human IL-27 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 80% to 102% with an overall mean recovery of 91%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | n.d.-405.59 | 75 | 68.41 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-12/IL-23 p40 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: IL-27
IL-27 is a heterodimeric group 2 receptor ligand molecule that belongs to the IL-6/IL-12 family of long type I cytokines. It is composed of EBI3 (EBV-induced gene 3), a 34 kDa glycoprotein that is related to the p40 subunit of IL-12 and IL-23, and p28, the 28 kDa glycoprotein that is related to the p35 chain of IL-12. The human EBI3 gene encodes a 229 amino acid (aa) precursor that contains a 20 aa signal peptide and 209 aa mature protein. The mature region contains two potential N-linked glycosylation sites, two fibronectin type III domains, and two pairs of conserved cysteine residues with a WSXWS-like motif that places the molecule in the hematopoietin receptor family. Although p40, the EBI3 counterpart in IL-12, is known to form homodimers, there is no evidence to date that EBI3 also homodimerizes. Human EBI3 is 61% aa identical to mouse EBI3. The human p28 gene encodes a 243 aa precursor that contains a 28 aa signal sequence and 215 aa mature region. The mature region is characterized by the presence of four alpha -helices, placing it in the IL-6 family of helical cytokines. Human p28 is 74% aa identical to mouse p28. IL-27 is expressed by monocytes, endothelial cells and dendritic cells. IL-27 binds to and signals through a heterodimeric receptor complex composed of WSX-1 (TCCR) and gp130. Evidence suggests IL-27 interacts only with WSX-1. IL-27 has both anti- and proinflammatory properties. As an anti-inflammatory, IL-27 seems to induce a general negative feedback program that limits T and NK-T cell activity. At the onset of infection, IL-27 induces an IL-12 receptor on naïve CD4+ T cells, making them susceptible to subsequent IL-12 activity (and possible Th1 development).
